metoclopramide has been researched along with Cervicogenic Headache in 3 studies
Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.
metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metoclopramide was not associated with lower headache risk on propensity score matching [treated vs." | 1.48 | No association between metoclopramide treatment in ED and reduced risk of post-concussion headache. ( Aglipay, M; Barlow, K; Barrowman, NJ; Bresee, N; Dubrovsky, AS; Freedman, SB; Gravel, J; Ledoux, AA; Momoli, F; Richer, L; Zemek, R, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Friedman, BW | 2 |
| Irizarry, E | 2 |
| Cain, D | 1 |
| Caradonna, A | 1 |
| Minen, MT | 1 |
| Solorzano, C | 1 |
| Zias, E | 1 |
| Zybert, D | 1 |
| McGregor, M | 1 |
| Bijur, PE | 1 |
| Gallagher, EJ | 1 |
| Babbush, K | 1 |
| White, D | 1 |
| John Gallagher, E | 1 |
| Bresee, N | 1 |
| Aglipay, M | 1 |
| Dubrovsky, AS | 1 |
| Ledoux, AA | 1 |
| Momoli, F | 1 |
| Gravel, J | 1 |
| Freedman, SB | 1 |
| Barlow, K | 1 |
| Richer, L | 1 |
| Barrowman, NJ | 1 |
| Zemek, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Placebo Controlled Trial of IV Metoclopramide for Acute Post-traumatic Headache[NCT03220958] | Phase 3 | 160 participants (Actual) | Interventional | 2017-08-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Improvement in this 0 to 10 verbal rating scale (NCT03220958)
Timeframe: 1 hour after medication administration
| Intervention | units on a scale (Mean) |
|---|---|
| Metoclopramide | 5.2 |
| Placebo | 3.8 |
"Number of days with any headache. Participants report the actual number of days they experienced headache. A day begins when they awake for the beginning of daily activities and ends when they go to sleep after completion of daily activities" (NCT03220958)
Timeframe: 7 days after ED visit
| Intervention | days (Mean) |
|---|---|
| Metoclopramide | 3.3 |
| Placebo | 3.3 |
Achieving a headache intensity of mild or none in the ED without use of rescue medication and maintaining a level of mild or none. Participants rate their headache as none, mild, moderate, or severe (NCT03220958)
Timeframe: 48 hours after medication administration
| Intervention | Participants (Count of Participants) |
|---|---|
| Metoclopramide | 24 |
| Placebo | 18 |
2 trials available for metoclopramide and Cervicogenic Headache
| Article | Year |
|---|---|
Randomized Study of Metoclopramide Plus Diphenhydramine for Acute Posttraumatic Headache.
Topics: Acute Pain; Administration, Intravenous; Adult; Diphenhydramine; Dopamine D2 Receptor Antagonists; D | 2021 |
An exploratory study of IV metoclopramide+diphenhydramine for acute post-traumatic headache.
Topics: Acute Pain; Diphenhydramine; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Dou | 2018 |
1 other study available for metoclopramide and Cervicogenic Headache
| Article | Year |
|---|---|
No association between metoclopramide treatment in ED and reduced risk of post-concussion headache.
Topics: Administration, Intravenous; Adolescent; Canada; Child; Dopamine D2 Receptor Antagonists; Emergency | 2018 |